Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia

dc.contributor.authorMaciejewski, S.en_US
dc.contributor.authorHilleman, D.en_US
dc.contributor.cuauthorHilleman, Daniel E.en_US
dc.contributor.cuauthorMaciejewski, Stephanie R.en_US
dc.date.accessioned2014-06-27T13:41:03Z
dc.date.available2014-06-27T13:41:03Z
dc.date.issued2008en_US
dc.date.monthMayen_US
dc.date.year2008en_US
dc.description.issue5en_US
dc.description.pages570-575en_US
dc.description.volume28en_US
dc.identifier.citationMaciejewski, S. and Hilleman, D. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Pharmacotherapy. 2008, MAY. 28(5):570-575.en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn0277-0008en_US
dc.identifier.pmid18447655en_US
dc.identifier.urihttp://hdl.handle.net/10504/58655
dc.program.unitSchool of Medicineen_US
dc.program.unitDepartment of Medicineen_US
dc.program.unitCardiologyen_US
dc.program.unitSchool of Pharmacy and Health Professionsen_US
dc.titleEffectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemiaen_US
dc.title.workPharmacotherapyen_US
dc.typeJournal Articleen_US
dc.url.link1http://dx.doi.org/10.1592/phco.28.5.570en_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: